Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07478952
PHASE1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Sponsor: ModernaTX, Inc.

View on ClinicalTrials.gov

Summary

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Official title: A Phase 1, Randomized, Open-label Study to Evaluate Safety, Reactogenicity, and Immunogenicity of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, Following Intradermal and Intramuscular Delivery in Healthy Adults 18 to 30 Years of Age

Key Details

Gender

All

Age Range

18 Years - 30 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-03-17

Completion Date

2027-05-15

Last Updated

2026-03-24

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

mRNA-1189

Sterile liquid for injection

Locations (2)

Nucleus Network

Melbourne, Victoria, Australia

Doherty Clinical Trials

Melbourne, Victoria, Australia